Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr;34(4):e23141.
doi: 10.1002/jcla.23141. Epub 2020 Jan 15.

Katanin P80 correlates with larger tumor size, lymph node metastasis, and advanced TNM stage and predicts poor prognosis in non-small-cell lung cancer patients

Qing Ye  1 , Min Zhang  2 , Yiping Yin  1
Affiliations

Katanin P80 correlates with larger tumor size, lymph node metastasis, and advanced TNM stage and predicts poor prognosis in non-small-cell lung cancer patients

Qing Ye et al. J Clin Lab Anal. 2020 Apr.

Abstract

Objective: The present study aimed to investigate the correlation of katanin P80 expression with clinicopathological features and survival profile in non-small-cell lung cancer (NSCLC) patients.

Methods: Totally, 398 NSCLC patients treated by pulmonary resection were enrolled and their tumor specimens were collected to determine katanin P80 expression by immunohistochemistry (IHC) assay. Clinical data were collected at diagnosis, and survival data including disease-free survival (DFS) and overall survival (OS) were assessed after treatment.

Results: There were 195 (49.0%) patients with katanin P80 high expression and 203 (51.0%) patients with katanin P80 low expression, respectively. Meanwhile, katanin P80 high expression was associated with larger tumor size (P = .001), lymph node (LYN) metastasis (P = .005), and advanced TNM stage (P = .001). As for survival data, katanin P80 high expression was correlated with reduced DFS (P < .001) and OS (P < .001). And forward stepwise multivariate Cox's regression revealed that katanin P80 high expression was an independent predictor for decreased DFS (P < .001) and OS (P < .001). Besides, further analysis indicated that DFS (P < .001) and OS (P < .001) were the shortest in patients with katanin P80 high+++ expression, followed by patients with katanin P80 high++ expression and then those with katanin P80 high + expression and katanin P80 low expression.

Conclusion: Katanin P80 correlates with larger tumor size, LYN metastasis, and advanced TNM stage, and serves as a potential biomarker for predicting poor survival in NSCLC patients.

Keywords: Katanin P80; disease-free survival; non-small-cell lung cancer; overall survival; tumor features.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study flow. NSCLC, non–small‐cell lung cancer
Figure 2
Figure 2
Different levels of katanin P80 expression samples in NSCLC patients. NSCLC, non–small‐cell lung cancer
Figure 3
Figure 3
Disease‐free survival (DFS) among NSCLC patients with different katanin P80 expression. Comparison of DFS between patients with katanin P80 high expression and patients with katanin P80 low expression (A). Comparison of DFS among patients with katanin P80 high+++ expression, patients with katanin P80 high++ expression, patients with katanin P80 high + expression, and those with katanin P80 low expression (B). DFS curve was constructed using Kaplan‐Meier method and determined by the log‐rank test between/among groups. P < .05 was considered significant. DFS, disease‐free survival; NSCLC, non–small‐cell lung cancer
Figure 4
Figure 4
Overall survival (OS) among NSCLC patients with different katanin P80 expression. Comparison of OS between patients with katanin P80 high expression and patients with katanin P80 low expression (A). Comparison of OS among patients with katanin P80 high+++ expression, patients with katanin P80 high++ expression, patients with katanin P80 high + expression, and those with katanin P80 low expression (B). OS curve was constructed using Kaplan‐Meier method and determined by the log‐rank test among groups. P < .05 was considered significant. OS, overall survival; NSCLC, non–small‐cell lung cancer
See this image and copyright information in PMC

References

    1. Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1‐19. - PubMed
    1. Novello S, Barlesi F, Califano R, et al. Metastatic non‐small‐cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2016;27(suppl 5):v1‐v27. - PubMed
    1. Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non‐small‐cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2017;28(suppl_4):iv1‐iv21. - PubMed
    1. Voltolini L, Paladini P, Luzzi L, et al. Iterative surgical resections for local recurrent and second primary bronchogenic carcinoma. Eur J Cardiothorac Surg. 2000;18(5):529‐534. - PubMed
    1. Hamaji M, Allen MS, Cassivi SD, et al. Surgical treatment of metachronous second primary lung cancer after complete resection of non‐small cell lung cancer. J Thorac Cardiovasc Surg. 2013;145(3):683‐691. - PubMed

Substances